Parkinson’s Disease Treatment Market Size, Growth and Analysis Report 2034
Global Parkinson’s Disease Treatment Market Growth, Size, Trends Analysis – By Drug Class, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: HLCA25199 | Pages: 1 - 250 | Formats*: |
| Category : Healthcare | |||
Global Parkinson’s Disease Treatment Market Introduction and Overview
According to SPER Market Research, the Global Parkinson’s Disease Treatment Market is estimated to reach USD 9.33 billion by 2034 with a CAGR of 5.33%.
The report includes an in-depth analysis of the Global Parkinson’s Disease Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. The global market for Parkinson's disease (PD) treatments is expanding significantly due to a number of important causes. The rising incidence of Parkinson's disease, especially in older populations, is a significant contributing factor. The number of people with Parkinson's disease (PD) is predicted to climb as life expectancy rises globally, increasing the patient population and fueling the need for efficient therapies. Drug development breakthroughs are also essential for market growth.
By Drug Class Insights
The carbidopa-levodopa sector dominates the Parkinson's disease therapy market and generate the biggest revenue share in recent years due to its long-standing effectiveness in treating symptoms, especially bradykinesia, stiffness, and tremors. By addressing the dopamine shortage in the brain, the combo therapy helps patients' motor function and quality of life. Due to its cost-effectiveness, accessibility, and track record, it is the first-line treatment for Parkinson's disease.
By Distribution Channel Insights
The retail pharmacy sector, which dominated the market for Parkinson's disease treatments, is expected to increase at the fastest rate over the course of the forecast period due to its widespread accessibility and patient convenience. Prescription drugs such as dopamine agonists, carbidopa-levodopa, and other therapies for Parkinson's disease symptoms are primarily distributed through retail pharmacies. Many patients wanting recurring care and refills are advantageous to this area.
Regional Insights
North America led the market for Parkinson's disease treatments due to a number of variables, including a high prevalence of the condition, sophisticated healthcare infrastructure, and substantial investments in research and development Strong healthcare infrastructure and a high rate of early diagnosis in the area help to increase the number of patients receiving Parkinson's disease therapies. The existence of significant pharmaceutical firms and government programs targeted at enhancing patient care also contributes to market expansion.
Market Competitive Landscape
The Parkinson’s Disease Treatment market is dominated by established players such as AbbVie, Inc., Amneal Pharmaceuticals LLC, Cerevel Therapeutics, GlaxoSmithKline plc. (GSK), H. Lundbeck A/S, as well as a number of small and medium-sized companies. These market participants frequently use tactics to increase their market presence and diversify their product lines, including mergers and acquisitions, strategic alliances, and intensive R&D. These businesses concentrate on creating cutting-edge medication formulations, such as combination and extended-release treatments, to improve patient compliance and treatment effectiveness.
Recent Developments:
In In October 2024, MeiraGTx reported encouraging findings from their clinical bridging study of AAV-GAD for Parkinson's disease, fulfilling safety and efficacy standards. Participants receiving the high dose experienced notable motor improvements, demonstrated by an 18-point gain in UPDRS Part 3 scores after 26 weeks. Additionally, both low- and high-dose groups showed marked enhancement in quality of life, as reflected in improved PDQ-39 scores. The therapy was well-tolerated across all participants, with no reports of serious adverse effects, supporting the progression to Phase 3 clinical trials.
In September 2024, CREXONT (carbidopa and levodopa) extended-release capsules were introduced by Amneal Pharmaceuticals to treat Parkinson's disease. In contrast to conventional immediate-release choices, the product's unique formulation blends immediate-release granules with extended-release pellets to provide a longer duration of effective symptom control with fewer doses. Pharmacy pharmacies in the United States now carry CREXONT, which is backed by affordability services. In September 2024, Amneal intends to introduce CREXONT at the International Congress on Parkinson's Disease and Movement Disorders. The goal of the drug is to efficiently treat Parkinson's disease symptoms.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Drug Class, By Distribution Channel |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | AbbVie, Inc., Amneal Pharmaceuticals LLC, Cerevel Therapeutics, GlaxoSmithKline plc. (GSK), H. Lundbeck A/S, Merck & Co., Inc., Novartis AG, Supernus Pharmaceuticals, Inc. Teva Pharmaceutical Industries Ltd. |
Key Topics Covered in the Report
- Global Parkinson’s Disease Treatment Market Size (FY’2021-FY’2034)
- Overview of Global Parkinson’s Disease Treatment Market
- Segmentation of Global Parkinson’s Disease Treatment Market by Drug Class (Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT inhibitors, Anticholinergics, Others)
- Segmentation of Global Parkinson’s Disease Treatment Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
- Statistical Snap of Global Parkinson’s Disease Treatment Market
- Expansion Analysis of Global Parkinson’s Disease Treatment Market
- Problems and Obstacles in Global Parkinson’s Disease Treatment Market
- Competitive Landscape in the Global Parkinson’s Disease Treatment Market
- Details on Current Investment in Global Parkinson’s Disease Treatment Market
- Competitive Analysis of Global Parkinson’s Disease Treatment Market
- Prominent Players in the Global Parkinson’s Disease Treatment Market
- SWOT Analysis of Global Parkinson’s Disease Treatment Market
- Global Parkinson’s Disease Treatment Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Parkinson’s Disease Treatment Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Parkinson’s Disease Treatment Market
7.Global Parkinson’s Disease Treatment Market, By Drug Class (USD Million) 2021-2034
7.1.Carbidopa-Levodopa7.2.Dopamine Agonists7.3.MAO-B Inhibitors7.4.COMT inhibitors7.5.Anticholinergics7.6.Others
8.Global Parkinson’s Disease Treatment Market, By Distribution Channel (USD Million) 2021-2034
8.1.Hospital Pharmacy8.2.Retail Pharmacy8.3.Online Pharmacy
9.Global Parkinson’s Disease Treatment Market, (USD Million) 2021-2034
9.1.Global Parkinson’s Disease Treatment Market Size and Market Share
10.Global Parkinson’s Disease Treatment Market, By Region, (USD Million) 2021-2034
10.1.Asia-Pacific
10.1.1.Australia10.1.2.China10.1.3.India10.1.4.Japan10.1.5.South Korea10.1.6.Rest of Asia-Pacific
10.2.Europe
10.2.1.France10.2.2.Germany10.2.3.Italy10.2.4.Spain10.2.5.United Kingdom10.2.6.Rest of Europe
10.3.Middle East and Africa
10.3.1.Kingdom of Saudi Arabia10.3.2.United Arab Emirates10.3.3.Qatar10.3.4.South Africa10.3.5.Egypt10.3.6.Morocco10.3.7.Nigeria10.3.8.Rest of Middle East and Africa
10.4.North America
10.4.1.Canada10.4.2.Mexico10.4.3.United States
10.5.Latin America
10.5.1.Argentina10.5.2.Brazil10.5.3.Rest of Latin America
11.Company Profile
11.1.AbbVie, Inc
11.1.1.Company details11.1.2.Financial outlook11.1.3.Product summary11.1.4.Recent developments
11.2.Amneal Pharmaceuticals LLC
11.2.1.Company details11.2.2.Financial outlook11.2.3.Product summary11.2.4.Recent developments
11.3.Cerevel Therapeutics
11.3.1.Company details11.3.2.Financial outlook11.3.3.Product summary11.3.4.Recent developments
11.4.GlaxoSmithKline plc. (GSK)
11.4.1.Company details11.4.2.Financial outlook11.4.3.Product summary11.4.4.Recent developments
11.5.H. Lundbeck A/S
11.5.1.Company details11.5.2.Financial outlook11.5.3.Product summary11.5.4.Recent developments
11.6.Merck & Co., Inc
11.6.1.Company details11.6.2.Financial outlook11.6.3.Product summary11.6.4.Recent developments
11.7.Novartis AG
11.7.1.Company details11.7.2.Financial outlook11.7.3.Product summary11.7.4.Recent developments
11.8.Supernus Pharmaceuticals, Inc.
11.8.1.Company details11.8.2.Financial outlook11.8.3.Product summary11.8.4.Recent developments
11.9.Teva Pharmaceutical Industries Ltd.
11.9.1.Company details11.9.2.Financial outlook11.9.3.Product summary11.9.4.Recent developments
11.10.Others
12.Conclusion
13.List of Abbreviations
14.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Parkinson’s Disease Treatment Market CAGR of 5.33% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Parkinson’s Disease Treatment Market size is USD 9.33 billion from 2025 to 2034.
Parkinson’s Disease Treatment Market is covered By Drug Class, By Distribution Channel
The North America is anticipated to have the highest Market share in the Parkinson’s Disease Treatment Market.
AbbVie, Inc., Amneal Pharmaceuticals LLC, Cerevel Therapeutics, GlaxoSmithKline plc. (GSK), H. Lundbeck A/S, Merck & Co., Inc., Novartis AG, Supernus Pharmaceuticals, Inc. Teva Pharmaceutical Industries Ltd.
The report includes an in-depth analysis of the Global Parkinson’s Disease Treatment Market, including market size and trends, product mix, Applications, and supplier analysis.
Parkinson’s Disease Treatment Market is projected to reach USD 9.33 billion by 2034, growing at a CAGR of of 5.33% during the forecast period.
Parkinson’s Disease Treatment Market grew in Market size from 2025. The Market is expected to reach USD 9.33 billion by 2034, at a CAGR of 5.33% during the forecast period.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
